Paper Details

  1. Home
  2. Paper Details

Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).

Author: AdamsDavid R, BaillieGeorge S, CameronRyan T, ColemanRyan G, DayJon P, HouslayMiles D, ShoichetBrian K, YallaKrishna C

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Moexipril, an angiotensin-converting enzyme (ACE) inhibitor, was identified as a PDE4 inhibitor. Moexipril and its analogues inhibited PDE4 activity in the micro molar range, increased intracellular cAMP levels, and induced phosphorylation of the small heat shock protein, Hsp20. This suggests that moexipril may be a potential starting point for the development of novel PDE4 inhibitors with improved therapeutic window.
Paper Details　
Original Abstract of the Article :
PDE4 is one of eleven known cyclic nucleotide phosphodiesterase families and plays a pivotal role in mediating hydrolytic degradation of the important cyclic nucleotide second messenger, cyclic 3'5' adenosine monophosphate (cAMP). PDE4 inhibitors are known to have anti-inflammatory properties, but t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3625111/

データ提供：米国国立医学図書館（NLM）

Moexipril: A New Role in the Fight Against Inflammation

This research explores the potential of moexipril, a well-established angiotensin-converting enzyme (ACE) inhibitor, as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4). PDE4 plays a crucial role in regulating inflammation, and inhibitors of this enzyme have shown promise in treating inflammatory conditions.

Moexipril: A Multifaceted Drug with Anti-Inflammatory Potential

The study utilized a high-throughput computational approach to identify moexipril as a potential PDE4 inhibitor. Experimental validation confirmed this finding, demonstrating that moexipril and its analogues effectively inhibited PDE4 activity. Furthermore, the study showed that moexipril significantly increased intracellular cAMP levels, suggesting its potential to modulate inflammatory pathways.

Moexipril: A Potential New Tool for Treating Inflammatory Conditions

This research suggests that moexipril, a safe and well-tolerated drug, could potentially be repurposed as a PDE4 inhibitor. This discovery opens up new avenues for exploring the therapeutic potential of moexipril in treating a variety of inflammatory conditions. Just as a camel's hump provides a reserve of energy for long desert treks, repurposing existing drugs can provide new solutions to healthcare challenges.

Dr.Camel's Conclusion

This study demonstrates the power of repurposing existing drugs to treat new conditions. It's a reminder that even in the vast desert of scientific knowledge, there are hidden gems waiting to be discovered. By exploring the potential of existing drugs in novel ways, we can pave the way for new treatments and improve the lives of countless patients.

Date :
  1. Date Completed 2013-05-21
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

23473803

DOI: Digital Object Identifier

PMC3625111

Related Literature

Article Analysis
・Effects of moexipril
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.